These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 25677426)

  • 1. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
    Bayés-Genís A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2015 Feb; 65(7):657-65. PubMed ID: 25677426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
    Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
    Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study.
    Bayés-Genís A; Barallat J; Pascual-Figal D; Nuñez J; Miñana G; Sánchez-Mas J; Galan A; Sanchis J; Zamora E; Pérez-Martínez MT; Lupón J
    JACC Heart Fail; 2015 Aug; 3(8):641-4. PubMed ID: 26251092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.
    Vodovar N; Séronde MF; Laribi S; Gayat E; Lassus J; Januzzi JL; Boukef R; Nouira S; Manivet P; Samuel JL; Logeart D; Cohen-Solal A; Richards AM; Launay JM; Mebazaa A;
    JACC Heart Fail; 2015 Aug; 3(8):629-36. PubMed ID: 26251090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responder to BNP-guided treatment in heart failure. The process of defining a responder.
    Karlström P; Dahlström U; Boman K; Alehagen U
    Scand Cardiovasc J; 2015; 49(6):316-24. PubMed ID: 26153427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.
    Goliasch G; Pavo N; Zotter-Tufaro C; Kammerlander A; Duca F; Mascherbauer J; Bonderman D
    Eur J Heart Fail; 2016 Jan; 18(1):89-93. PubMed ID: 26725876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.
    Mogensen UM; Jhund PS; Abraham WT; Desai AS; Dickstein K; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Køber L; McMurray JJV;
    J Am Coll Cardiol; 2017 Nov; 70(20):2490-2500. PubMed ID: 29145948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the angiotensin-receptor-neprilysin inhibitor in heart failure patients with left ventricular ejection fraction higher than 40.
    Zhao M; Xin Y; Li J; Cao X; Liu X
    Medicine (Baltimore); 2019 Sep; 98(39):e17296. PubMed ID: 31574852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial.
    Girerd N; Pang PS; Swedberg K; Fought A; Kwasny MJ; Subacius H; Konstam MA; Maggioni A; Gheorghiade M; Zannad F;
    Eur J Heart Fail; 2013 Nov; 15(11):1228-35. PubMed ID: 23787720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Outcomes of Pneumonia in Patients With Heart Failure.
    Shen L; Jhund PS; Anand IS; Bhatt AS; Desai AS; Maggioni AP; Martinez FA; Pfeffer MA; Rizkala AR; Rouleau JL; Swedberg K; Vaduganathan M; Vardeny O; van Veldhuisen DJ; Zannad F; Zile MR; Packer M; Solomon SD; McMurray JJV
    J Am Coll Cardiol; 2021 Apr; 77(16):1961-1973. PubMed ID: 33888245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure.
    Gommans DHF; Revuelta-Lopez E; Lupon J; Cserkóová A; Domingo M; Vart P; van Royen N; Bayés-Genis A; van Kimmenade RRJ
    JACC Heart Fail; 2021 Feb; 9(2):85-95. PubMed ID: 33189629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction.
    Koller L; Kleber ME; Brandenburg VM; Goliasch G; Richter B; Sulzgruber P; Scharnagl H; Silbernagel G; Grammer TB; Delgado G; Tomaschitz A; Pilz S; Berger R; Mörtl D; Hülsmann M; Pacher R; März W; Niessner A
    Circ Heart Fail; 2015 Nov; 8(6):1059-67. PubMed ID: 26273098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.
    Prausmüller S; Arfsten H; Spinka G; Freitag C; Bartko PE; Goliasch G; Strunk G; Pavo N; Hülsmann M
    J Am Heart Assoc; 2020 Jun; 9(11):e015071. PubMed ID: 32427034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
    Nadruz W; Claggett BL; McMurray JJ; Packer M; Zile MR; Rouleau JL; Desai AS; Swedberg K; Lefkowitz M; Shi VC; Prescott MF; Solomon SD
    Circulation; 2016 Nov; 134(22):1785-1787. PubMed ID: 27895026
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure.
    Rychli K; Richter B; Hohensinner PJ; Kariem Mahdy A; Neuhold S; Zorn G; Berger R; Mörtl D; Huber K; Pacher R; Wojta J; Niessner A; Hülsmann M
    Heart; 2011 Jul; 97(14):1158-63. PubMed ID: 21572126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.
    Vardeny O; Claggett B; Udell JA; Packer M; Zile M; Rouleau J; Swedberg K; Desai AS; Lefkowitz M; Shi V; McMurray JJV; Solomon SD;
    JACC Heart Fail; 2016 Feb; 4(2):152-158. PubMed ID: 26746371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure.
    Núñez J; Núñez E; Barallat J; Bodí V; Miñana G; Pastor MC; Sanchis J; Lupón J; Bayes-Genis A
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.